Articles by Jenel Stelton-Holtmeier :
This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.
Given the skyrocketing demand for cannabis and its newly found legitimacy, we anticipate increased government scrutiny and a need for more testing.
Sales growth rates play a huge role in determining the value of a cannabis investment. However, growth analysis is rarely a clean or simple task.
Visions dance in the heads of key players of entire aisles in grocery stores and pharmacies dominated by marijuana and hemp products. Behind that, of course, there are visions of dynastic wealth.
Because of the rapidly evolving legal and regulatory environment at the federal and state levels, barriers to entry play a huge factor in the cannabis industry.
Due diligence helps an investor frame an investment opportunity and, more importantly, to gauge the risks. Experienced investors understand this, but it can be easy to overlook critical elements of the process.
This has been a roller-coaster year for cannabis stocks, a signal that investors are assessing the opportunity more critically than they have before.
Curaleaf continued its march to become a truly national cannabis company with its $875 million acquisition of Grassroots, one of the largest private multistate operators (MSO) in the United States.
Biosynthesis – the mass production of specific cannabinoids in a lab setting – might be setting up to be the next big disruptor for the cannabis industry.